Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Pediatr Blood Cancer. 2012 Jun 28;60(3):363–370. doi: 10.1002/pbc.24238

Figure 1.

Figure 1

Four subsets of peripheral neuroblastic tumors by MYCN status and histopathology classification for all patients registered in the Children’s Cancer Group and the Children’s Oncology Group studies (n=4,706). A: Pie-graph illustrating the proportion of patients in those subsets with an arrow pointing to the genotype-phenotype discordant subset. B: Kaplan–Meier curve for event-free survival of patients in those subsets. C: Kaplan–Meier curve for overall survival of patients in those subsets; Non-Amp & FH, MYCN non-amplified and Favorable Histology subset; Non-Amp & UH, MYCN non-amplified and Unfavorable Histology subset; Amp & FH, MYCN amplified and Favorable Histology subset; Amp & UH, MYCN amplified and Unfavorable Histology subset.